Abstract
Cellular homeostasis relies on quality control systems so that damaged biologic structures are either repaired or degraded and entirely replaced by newly formed proteins or even organelles. The clearance of dysfunctional cellular structures in long-lived postmitotic cells, like neurons, is essential to eliminate, per example, defective mitochondria, lipofuscin-loaded lysosomes and oxidized proteins. Short-lived proteins are degraded mainly by proteases and proteasomes whether most long-lived proteins and all organelles are digested by autophagy in the lysosomes. Recently, it an interplay was established between the ubiquitin-proteasome system and macroautophagy, so that both degradative mechanisms compensate for each other. In this article we describe each of these clearance systems and their contribution to neuronal quality control. We will highlight some of the findings that provide evidence for the dysfunction of these systems in Alzheimers and Parkinsons diseases. Ultimately, we provide an outline on potential therapeutic interventions based on the modulation of cellular degradative systems.
Keywords: Macroautophagy, proteasome, ubiquitin, protein aggregates, mitochondria, Parkin-mediated mitophagy, neurodegeneration, oxidative stress, Aβ peptide, apoptosis
Current Pharmaceutical Design
Title: Therapeutic Intervention at Cellular Quality Control Systems in Alzheimers and Parkinsons Diseases
Volume: 17 Issue: 31
Author(s): Daniela M. Arduino, A. Raquel Esteves, Diana F.F. Silva, Diogo Martins-Branco, Daniel Santos, Diana F. Gomes Pimentel and Sandra M. Cardoso
Affiliation:
Keywords: Macroautophagy, proteasome, ubiquitin, protein aggregates, mitochondria, Parkin-mediated mitophagy, neurodegeneration, oxidative stress, Aβ peptide, apoptosis
Abstract: Cellular homeostasis relies on quality control systems so that damaged biologic structures are either repaired or degraded and entirely replaced by newly formed proteins or even organelles. The clearance of dysfunctional cellular structures in long-lived postmitotic cells, like neurons, is essential to eliminate, per example, defective mitochondria, lipofuscin-loaded lysosomes and oxidized proteins. Short-lived proteins are degraded mainly by proteases and proteasomes whether most long-lived proteins and all organelles are digested by autophagy in the lysosomes. Recently, it an interplay was established between the ubiquitin-proteasome system and macroautophagy, so that both degradative mechanisms compensate for each other. In this article we describe each of these clearance systems and their contribution to neuronal quality control. We will highlight some of the findings that provide evidence for the dysfunction of these systems in Alzheimers and Parkinsons diseases. Ultimately, we provide an outline on potential therapeutic interventions based on the modulation of cellular degradative systems.
Export Options
About this article
Cite this article as:
M. Arduino Daniela, Raquel Esteves A., F.F. Silva Diana, Martins-Branco Diogo, Santos Daniel, F. Gomes Pimentel Diana and M. Cardoso Sandra, Therapeutic Intervention at Cellular Quality Control Systems in Alzheimers and Parkinsons Diseases, Current Pharmaceutical Design 2011; 17 (31) . https://dx.doi.org/10.2174/138161211798072481
DOI https://dx.doi.org/10.2174/138161211798072481 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Modulation of ABC Transporters by Nuclear Receptors: Physiological, Pathological and Pharmacological Aspects
Current Medicinal Chemistry Receptor-Independent Effects of Endocannabinoids on Ion Channels
Current Pharmaceutical Design Editorial: Brain Imaging and Automatic Analysis in Neurological and Psychiatric Diseases – Part II
CNS & Neurological Disorders - Drug Targets Addressing Unmet Medical Needs in Type 1 Diabetes: A Review of Drugs Under Development
Current Diabetes Reviews Are B Cells a Potential Target for Therapeutic Intervention in the Classical T Cell-Mediated Autoimmune Disease Type 1 Diabetes?
Inflammation & Allergy - Drug Targets (Discontinued) Neurodegenerative Disorders and Cholesterol
Current Alzheimer Research Social Networks and Health in Women: Results from a Qualitative Study in Iran
Current Women`s Health Reviews Clinical Pharmacogenetics and Potential Application in Personalized Medicine
Current Drug Metabolism Sleep-Inducing Factors
CNS & Neurological Disorders - Drug Targets Anti-Copper Therapies in Alzheimers Disease: New Concepts
Recent Patents on CNS Drug Discovery (Discontinued) Acute Tonsillitis
Infectious Disorders - Drug Targets DNMT3B Promoter Polymorphisms and Risk of Late Onset Alzheimer’s Disease
Current Alzheimer Research Editorial: Can Hangover Immunity be Really Claimed?
Current Drug Abuse Reviews Advantages of Structure-Based Drug Design Approaches in Neurological Disorders
Current Neuropharmacology Can Molecular Biology Propose Reliable Biomarkers for Diagnosing Major Depression?
Current Pharmaceutical Design Molecular Dynamics and Regulation of Butyrylcholinesterase Cholinergic Activity by RNA Binding Proteins
CNS & Neurological Disorders - Drug Targets NF-κB Signaling and Carcinogenesis
Current Pharmaceutical Design Scorpion Toxins Targeting Voltage-gated Sodium Channels Associated with Pain
Current Pharmaceutical Biotechnology Alcoholic Hepatitis: Pathogenesis, Diagnosis and Treatment
Reviews on Recent Clinical Trials Editorial [Hot Topic: Inflammation as Target for Pharmaceutical Intervention in Cancer (Executive Editors: R.M. Schiffelers and K.E. de Visser)]
Current Pharmaceutical Design